Mangoceuticals (NASDAQ:MGRX) Announces Earnings Results

by · The Cerbat Gem

Mangoceuticals (NASDAQ:MGRX – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.22) EPS for the quarter, FiscalAI reports. Mangoceuticals had a negative net margin of 4,536.70% and a negative return on equity of 109.38%. The firm had revenue of $0.07 million for the quarter.

Mangoceuticals Price Performance

Mangoceuticals stock traded up $0.01 during mid-day trading on Tuesday, reaching $0.41. 292,167 shares of the company traded hands, compared to its average volume of 8,424,372. Mangoceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $2.75. The company has a market capitalization of $7.01 million, a price-to-earnings ratio of -0.16 and a beta of 2.12. The firm’s fifty day moving average is $0.38 and its two-hundred day moving average is $0.72.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new stake in Mangoceuticals during the fourth quarter worth $1,137,000. Ikarian Capital LLC purchased a new stake in Mangoceuticals during the fourth quarter worth $102,000. Jane Street Group LLC purchased a new stake in Mangoceuticals during the fourth quarter worth $35,000. Boothbay Fund Management LLC purchased a new stake in Mangoceuticals during the fourth quarter worth $28,000. Finally, Virtu Financial LLC acquired a new stake in Mangoceuticals in the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wall Street Zen raised shares of Mangoceuticals to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Mangoceuticals presently has an average rating of “Sell”.

Get Our Latest Stock Analysis on Mangoceuticals

About Mangoceuticals

(Get Free Report)

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.

Read More